Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.
Muchtar E, Gertz MA, Lacy MQ, Go RS, Buadi FK, Dingli D, Grogan M, AbouEzzeddine OF, Hayman SR, Kapoor P, Leung N, Fonder A, Hobbs M, Hwa YL, Gonsalves W, Warsame R, Kourelis TV, Russell S, Lust JA, Lin Y, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Dispenzieri A. Muchtar E, et al. Among authors: zeldenrust s. Br J Haematol. 2019 Dec;187(5):588-594. doi: 10.1111/bjh.16096. Epub 2019 Jul 12. Br J Haematol. 2019. PMID: 31298751 Free PMC article.
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
Kumar S, Dispenzieri A, Katzmann JA, Larson DR, Colby CL, Lacy MQ, Hayman SR, Buadi FK, Leung N, Zeldenrust SR, Ramirez-Alvarado M, Clark RJ, Kyle RA, Rajkumar SV, Gertz MA. Kumar S, et al. Among authors: zeldenrust sr. Blood. 2010 Dec 9;116(24):5126-9. doi: 10.1182/blood-2010-06-290668. Epub 2010 Aug 26. Blood. 2010. PMID: 20798235 Free PMC article.
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA. Kumar S, et al. Among authors: zeldenrust sr. J Clin Oncol. 2012 Mar 20;30(9):989-95. doi: 10.1200/JCO.2011.38.5724. Epub 2012 Feb 13. J Clin Oncol. 2012. PMID: 22331953 Free PMC article.
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis.
Hwa YL, Warsame R, Gertz MA, Buadi FK, Lacy MQ, Kumar SK, Dingli D, Zeldenrust SR, Leung N, Hayman SR, Kapoor P, Gonsalves WI, Kourelis TV, Russell S, Go RS, Hobbs MA, Fonder AL, Rajkumar SV, Dispenzieri A. Hwa YL, et al. Among authors: zeldenrust sr. Blood. 2017 Sep 28;130(13):1578-1584. doi: 10.1182/blood-2017-05-783415. Epub 2017 Aug 14. Blood. 2017. PMID: 28807981 Free article.
Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.
Hwa YL, Gertz MA, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Kapoor P, Zeldenrust SR, Leung N, Hayman SR, Gonsalves WI, Kourelis TV, Warsame R, Go RS, Muchtar E, Hobbs MA, Fonder AL, Russell S, Kyle RA, Rajkumar SV, Dispenzieri A. Hwa YL, et al. Among authors: zeldenrust sr. Leukemia. 2019 May;33(5):1268-1272. doi: 10.1038/s41375-019-0400-5. Epub 2019 Feb 8. Leukemia. 2019. PMID: 30737485
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
Bryce AH, Ketterling RP, Gertz MA, Lacy M, Knudson RA, Zeldenrust S, Kumar S, Hayman S, Buadi F, Kyle RA, Greipp PR, Lust JA, Russell S, Rajkumar SV, Fonseca R, Dispenzieri A. Bryce AH, et al. Among authors: zeldenrust s. Haematologica. 2009 Mar;94(3):380-6. doi: 10.3324/haematol.13369. Epub 2009 Feb 11. Haematologica. 2009. PMID: 19211640 Free PMC article.
Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Kourelis TV, Gertz M, Zent C, Lacy M, Kyle R, Kapoor P, Zeldenrust S, Buadi F, Witzig T, Hayman S, Lust J, Russell S, Lin Y, Rajkumar VS, Kumar S, Leung N, Dingli D, Dispenzieri A. Kourelis TV, et al. Among authors: zeldenrust s. Am J Hematol. 2013 May;88(5):375-8. doi: 10.1002/ajh.23413. Epub 2013 Mar 19. Am J Hematol. 2013. PMID: 23508840 Free article.
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, Zeldenrust S, Leung N, Kyle RA, Russell S, Dingli D, Lust JA, Lin Y, Kapoor P, Rajkumar SV, McCurdy A, Dispenzieri A. Kourelis TV, et al. Among authors: zeldenrust s. J Clin Oncol. 2013 Dec 1;31(34):4319-24. doi: 10.1200/JCO.2013.50.8499. Epub 2013 Oct 21. J Clin Oncol. 2013. PMID: 24145344 Free PMC article.
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.
Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, Dingli D, Leung N, Zeldenrust S, Hayman SR, Kapoor P, Grogan M, Hwa L, Russell SJ, Go RS, Rajkumar SV, Kyle RA, Jaffe A. Dispenzieri A, et al. Among authors: zeldenrust s. Am J Hematol. 2015 Jun;90(6):524-8. doi: 10.1002/ajh.24001. Epub 2015 Apr 2. Am J Hematol. 2015. PMID: 25753178 Free article. Clinical Trial.
183 results